Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Pre- and Post-Transplant for CD20+ B-Cell Malignancies
NCT00867529Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in B-cell malignancy, sponsored by Fred Hutchinson Cancer Center. Started Feb 2009; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT00867529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867529.